Allos Therapeutics, Inc. Announces Interim Data from Phase 1 Study of PDX in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the presentation of interim data from its Phase 1 study of PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 4-7, 2008.
MORE ON THIS TOPIC